Get the Stockscreener App
18.48
1.96%
-0.37
Bicara Therapeutics Inc stock is traded at $18.48, with a volume of 2.09M.
It is down -1.96% in the last 24 hours and up +23.94% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$18.85
Open:
$18.97
24h Volume:
2.09M
Relative Volume:
3.06
Market Cap:
$1.01B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.54%
1M Performance:
+23.94%
6M Performance:
+59.72%
1Y Performance:
+2.41%
1-Day Range:
$18.32
$19.58
1-Week Range:
$18.08
$19.68
52-Week Range:
$7.80
$19.75
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.48 | 1.03B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - setenews.com
Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com Australia
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks
Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks
Bicara Therapeutics Inc Announces Preliminary Phase 1b Data - TradingView — Track All Markets
Bicara Therapeutics reports promising phase 1b data - MSN
Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating - TipRanks
Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa - TipRanks
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort - GlobeNewswire
Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Yahoo Finance
Will Bicara Therapeutics Inc. stock sustain high P E ratios2025 Biggest Moves & Verified Entry Point Detection - Newser
Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Stock Analysis Report | Financials & Insights - Benzinga
Does Bicara Therapeutics Inc (BCAX) offer a good opportunity for investors? - Setenews
Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating - TipRanks
Bicara’s ficerafusp alfa shows consistent response rates at lower dose By Investing.com - Investing.com Australia
Bicara Therapeutics (BCTX) Releases Promising Early Data from Ca - GuruFocus
Bicara’s ficerafusp alfa shows consistent response rates at lower dose - Investing.com
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 - GlobeNewswire
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 3.3%Time to Sell? - MarketBeat
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
What Analyst Ratings Reveal About Venus Pipes and Tubes Limiteds Future ValueShort-Term Trading Alerts & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
What’s Bicara Therapeutics Inc (BCAX)’s Price to Earnings Ratio? - fostersleader.com
[424B5] Bicara Therapeutics Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock - Investing.com Nigeria
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock By Investing.com - Investing.com South Africa
Bicara Therapeutics president Cohlhepp sells $225k in shares By Investing.com - Investing.com South Africa
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics president Cohlhepp sells $225k in shares - Investing.com
Bicara Therapeutics Executives Engage in Stock Sales - TradingView
Pres Cohlhepp Sells 12,500 ($225.6K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Officer Raben Sells 11,000 ($205.1K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout (NASDAQ:BCAX) - Seeking Alpha
Ready to Jump After Recent Trade: Bicara Therapeutics Inc (BCAX) - setenews.com
CFO Hyep Files To Sell 605 Of Bicara Therapeutics Inc [BCAX] - TradingView
How Bicara Therapeutics Inc. stock reacts to job market data2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 9.5%Still a Buy? - MarketBeat
Is Bicara Therapeutics Inc. stock safe for conservative investors - newser.com
Why Bicara Therapeutics Inc. stock appeals to analysts2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - newser.com
What risks investors should watch in Bicara Therapeutics Inc. stock2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com
Should I hold or sell Bicara Therapeutics Inc. stock in 2025Insider Buying & Reliable Momentum Entry Alerts - newser.com
What dividend safety score for Bicara Therapeutics Inc. stockWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hyep Ivan | Chief Financial Officer |
Nov 21 '25 |
Option Exercise |
3.79 |
605 |
2,293 |
145,960 |
| Hyep Ivan | Chief Financial Officer |
Nov 24 '25 |
Sale |
18.55 |
17,795 |
330,094 |
145,355 |
| Hyep Ivan | Chief Financial Officer |
Nov 21 '25 |
Sale |
18.15 |
605 |
10,981 |
145,355 |
| Cohlhepp Ryan | President and COO |
Nov 21 '25 |
Option Exercise |
3.79 |
8,000 |
30,318 |
206,141 |
| Cohlhepp Ryan | President and COO |
Nov 21 '25 |
Sale |
18.05 |
12,500 |
225,588 |
193,641 |
| Mazumdar Claire | Chief Executive Officer |
Nov 24 '25 |
Option Exercise |
3.79 |
41,163 |
156,000 |
351,055 |
| Mazumdar Claire | Chief Executive Officer |
Nov 24 '25 |
Sale |
18.86 |
41,163 |
776,429 |
309,892 |
| Raben David | Chief Medical Officer |
Nov 24 '25 |
Option Exercise |
3.79 |
5,500 |
20,844 |
40,997 |
| Raben David | Chief Medical Officer |
Nov 25 '25 |
Option Exercise |
3.79 |
5,500 |
20,844 |
40,091 |
| Raben David | Chief Medical Officer |
Nov 25 '25 |
Sale |
18.84 |
5,500 |
103,633 |
35,497 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):